Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-11-19Clinical Trial Update: R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma [Phase 2]
This update notes the completion of a Phase 2 trial evaluating first-line R-CHOP in combination with lenalidomide for diffuse large B-cell l…
-
CLINICAL_TRIALS trial_result · 2025-11-19Clinical Trial Update: Sequential CD19/CD22 CAR-T Cell Therapy Following ASCT [Phase 2]
Phase 2 trial evaluating sequential CD19/CD22 CAR-T cell therapy after autologous stem cell transplant in Diffuse large B-cell lymphoma; the…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study
This clinical trial update reports ongoing recruitment for a study aimed at identifying predictive factors for the efficacy of CD19 CAR-T th…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma [Phase 2]
This is a Phase 2 study evaluating a triple-drug regimen of glofitamab, polatuzumab vedotin, and zuberitamab in newly diagnosed diffuse larg…
-
CLINICAL_TRIALS trial_result · 2025-11-18Clinical Trial Update: Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell
This clinical trial update reports on a completed study evaluating the potential cardiotoxic effects of anthracycline chemotherapy in patien…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
A recruiting clinical study examining metabolic and immunomic differences in primary central nervous system lymphoma and diffuse large B-cel…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma
A clinical trial is recruiting to evaluate drug-eluting bead-based transarterial chemoembolization (DEB-TACE) as local salvage therapy for l…
-
CLINICAL_TRIALS other · 2025-11-18Clinical Trial Update: A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma [Phase 3]
A Phase 3 trial evaluating SHR-A1912 plus R-GemOx versus R-GemOx in Diffuse Large B-cell Lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: Emapalumab Prevention of CAR-T Cell Associated Toxicities [Phase 2]
A Phase 2 clinical trial update evaluating emapalumab for preventing CAR-T cell–related toxicities in patients with relapsed or refractory B…
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating CTX112 in relapsed or refractory B-cell malignancies is currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [Phase 1]
This document provides an update on a Phase 1 clinical trial evaluating the combination of lenalidomide and ibrutinib in patients with relap…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Long-term Follow-up Study of Patients Receiving CAR-T Cells
This clinical trial update outlines a long-term follow-up study of patients who received CAR-T cell therapy. Sponsored by the Medical Colleg…
-
CLINICAL_TRIALS trial_result · 2025-11-10Clinical Trial Update: Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant [Phase 1]
Phase 1 study evaluating olaparib in combination with high-dose chemotherapy for relapsed or refractory lymphomas undergoing stem cell trans…
-
EMA approval · 2025-11-06EMA Authorised: Kymriah (tisagenlecleucel) — Novartis Europharm Limited
The EMA authorised Kymriah (tisagenlecleucel) for additional indications in precursor B-cell lymphoblastic leukemia/lymphoma and diffuse lar…
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) [Phase 1]
Phase 1 clinical trial evaluating the combination of Rituximab and Tafasitamab with allogeneic NK cells in relapsed/refractory B-cell non-Ho…
-
CLINICAL_TRIALS trial_result · 2025-11-04Clinical Trial Update: A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study [Phase 1, Phase 2]
This document reports the completion of a long-term safety study of tazemetostat in adults who previously received the drug in earlier trial…
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: Hyperfractionated Dual Equivalent Fractionated Radiation Therapy [NA]
A clinical trial at Yale University is evaluating a hyperfractionated dual equivalent fractionated radiation therapy approach for Diffuse La…
-
CLINICAL_TRIALS trial_result · 2025-11-03Clinical Trial Update: Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies [Phase 2]
Phase 2 trial evaluating nivolumab in patients with hematologic malignancies after CAR-T therapy; results have been posted with the study cu…
-
EMA approval · 2025-10-24EMA Authorised: Columvi (Glofitamab) — Roche Registration GmbH
The EMA authorised Columvi (glofitamab) from Roche Registration GmbH for diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS research · 2025-10-23Clinical Trial Update: Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial [Phase 3]
Phase 3 PIRAMID trial evaluating adding pirtobrutinib to standard therapy for newly diagnosed Richter transformation (transformed CLL/SLL to…
-
CLINICAL_TRIALS trial_result · 2025-10-23Clinical Trial Update: Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy [Phase 1]
Phase 1 clinical trial evaluating NT-I7 after CD19 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma has completed. The tri…
-
CLINICAL_TRIALS trial_result · 2025-10-21Clinical Trial Update: A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) [Phase 1]
Regeneron's bbT369 Phase 1 study in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a form of B-cell non-Hodgkin's lymphoma, h…
-
CLINICAL_TRIALS research · 2025-10-20Clinical Trial Update: Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment [Phase 2]
This SWOG Cancer Research Network Phase 2 trial is evaluating adding drugs to standard therapy for large B-cell lymphoma that has returned o…
-
CLINICAL_TRIALS research · 2025-10-20Clinical Trial Update: A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL) [Phase 1]
Phase Ib study of VK-2019 in patients with EBV-positive diffuse large B-cell lymphoma (EBV+ DLBCL). The trial is currently recruiting.
-
CLINICAL_TRIALS research · 2025-10-20Clinical Trial Update: A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP [Phase 2]
This is a Phase 2 clinical trial investigating mosunetuzumab consolidation for older patients with diffuse large B-cell lymphoma who have de…